Dianthus Therapeutics, Inc. /DE/
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
DNTH$88.81-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenues: | ||
| License revenue | $463 | $1,163 |
| Operating expenses: | ||
| Research and development | 34,528 | 27,003 |
| General and administrative | 12,468 | 7,337 |
| Total operating expenses | 46,996 | 34,340 |
| Loss from operations | (46,533) | (33,177) |
| Other income/(expense): | ||
| Interest and investment income | 6,265 | 3,791 |
| Loss on investment in former related party | (302) | (5) |
| Loss on currency exchange, net | (15) | (22) |
| Other expense | (249) | (98) |
| Total other income | 5,699 | 3,666 |
| Net loss | $(40,834) | $(29,511) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.85) | $(0.82) |
| Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, basic and diluted | 48,032,742 | 35,790,700 |
| Comprehensive loss: | ||
| Net loss | $(40,834) | $(29,511) |
| Other comprehensive (loss)/income: | ||
| Unrealized (loss)/gain on marketable securities | (1,064) | 164 |
| Total other comprehensive (loss)/income | (1,064) | 164 |
| Total comprehensive loss | $(41,898) | $(29,347) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.